Zacks Research Has Bullish Forecast for EW Q3 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Equities research analysts at Zacks Research upped their Q3 2025 earnings estimates for shares of Edwards Lifesciences in a report issued on Wednesday, December 11th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $0.61 per share for the quarter, up from their previous estimate of $0.60. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q4 2025 earnings at $0.63 EPS, Q2 2026 earnings at $0.66 EPS, Q3 2026 earnings at $0.70 EPS and FY2026 earnings at $2.75 EPS.

Other analysts have also issued research reports about the company. Stifel Nicolaus upped their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a report on Thursday, December 5th. Evercore ISI cut their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Robert W. Baird decreased their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Wells Fargo & Company cut their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Finally, Jefferies Financial Group cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price target for the stock from $85.00 to $70.00 in a report on Wednesday, September 18th. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Hold” and an average target price of $78.65.

Edwards Lifesciences Trading Up 0.2 %

Shares of NYSE:EW opened at $73.97 on Friday. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market cap of $43.63 billion, a P/E ratio of 10.67, a P/E/G ratio of 3.63 and a beta of 1.12. The company has a 50 day moving average of $69.26 and a 200-day moving average of $74.19.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.59 EPS.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,262,521.36. This trade represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 35,000 shares of company stock valued at $2,323,150 in the last three months. Company insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences during the third quarter worth $32,000. Avior Wealth Management LLC lifted its holdings in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the period. HHM Wealth Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at $55,000. Finally, Peoples Bank KS acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $40,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.